SCHEMBL9926062

SCHEMBL9926062

Cc1ccc(C)c(N2CCN(C(=O)[C@@H]3CN(S(=O)(=O)c4cccnc4)C[C@H]3c3cccnc3)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 0.58
HTT P42858 3/20 0.58
NPSR1 Q6W5P4 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.51
MAPT P10636 4/20 0.51
CHRM1 P11229 1/20 0.50
NAMPT P43490 1/20 0.48
KMT2A Q03164 1/20 0.46
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADAM17 P78536 1/20 0.43
ADAMTS5 Q9UNA0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14269767 0.96 USP2 (0.57) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL9926136 0.96 USP2 (0.57) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL9926098 0.96 USP2 (0.57) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL9926135 0.90 USP2 (0.53) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL13987602 0.90 USP2 (0.56) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL9926058 0.89 USP2 (0.61) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL9926009 0.88 HTT (0.51) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL13987610 0.87 USP2 (0.54) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL14269756 0.87 USP2 (0.54) USP2HTTNPSR1SMN1; SMN2MAPT
SCHEMBL13987636 0.86 USP2 (0.64) USP2HTTNPSR1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836180-B1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI SA (FR) 2012-06-13 EP disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SLC5A1, SLC5A2, KCNJ1 USP2 3511/4885HTT 613/4885NPSR1 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.